157 related articles for article (PubMed ID: 28914772)
1. The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report.
Baybutt TR; Aka AA; Snook AE
Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28914772
[TBL] [Abstract][Full Text] [Related]
2. GUCY2C-targeted cancer immunotherapy: past, present and future.
Snook AE; Magee MS; Waldman SA
Immunol Res; 2011 Dec; 51(2-3):161-9. PubMed ID: 22038530
[TBL] [Abstract][Full Text] [Related]
3. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.
Snook AE; Magee MS; Marszalowicz GP; Schulz S; Waldman SA
Cancer Immunol Immunother; 2012 May; 61(5):713-23. PubMed ID: 22057677
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope.
Snook AE; Baybutt TR; Hyslop T; Waldman SA
Hum Gene Ther Methods; 2016 Dec; 27(6):238-250. PubMed ID: 27903079
[TBL] [Abstract][Full Text] [Related]
5. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
Aka AA; Rappaport JA; Pattison AM; Sato T; Snook AE; Waldman SA
Expert Rev Clin Pharmacol; 2017 May; 10(5):549-557. PubMed ID: 28162021
[TBL] [Abstract][Full Text] [Related]
6. An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer.
Rappaport JA; Waldman SA
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1125-1137. PubMed ID: 32945718
[No Abstract] [Full Text] [Related]
7. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.
Witek M; Blomain ES; Magee MS; Xiang B; Waldman SA; Snook AE
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1188-95. PubMed ID: 24661671
[TBL] [Abstract][Full Text] [Related]
8. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer.
Marszalowicz GP; Snook AE; Magee MS; Merlino D; Berman-Booty LD; Waldman SA
Oncotarget; 2014 Oct; 5(19):9460-71. PubMed ID: 25294806
[TBL] [Abstract][Full Text] [Related]
9. Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.
Flickinger JC; Rappaport JA; Barton JR; Baybutt TR; Pattison AM; Snook AE; Waldman SA
Biomark Med; 2021 Feb; 15(3):201-217. PubMed ID: 33470843
[TBL] [Abstract][Full Text] [Related]
10. ST-Producing E. coli Oppose Carcinogen-Induced Colorectal Tumorigenesis in Mice.
Li P; Lin JE; Snook AE; Waldman SA
Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28895923
[TBL] [Abstract][Full Text] [Related]
11. GUCY2C ligand replacement to prevent colorectal cancer.
Blomain ES; Pattison AM; Waldman SA
Cancer Biol Ther; 2016 Jul; 17(7):713-8. PubMed ID: 27104761
[TBL] [Abstract][Full Text] [Related]
12. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers.
Weinberg DS; Foster NR; Della'Zanna G; McMurray RP; Kraft WK; Pallotto A; Kastenberg DM; Katz LC; Henry CH; Moleski SM; Limburg PJ; Waldman SA
Cancer Biol Ther; 2021 Dec; 22(10-12):544-553. PubMed ID: 34632925
[TBL] [Abstract][Full Text] [Related]
13. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity.
Magee MS; Kraft CL; Abraham TS; Baybutt TR; Marszalowicz GP; Li P; Waldman SA; Snook AE
Oncoimmunology; 2016; 5(10):e1227897. PubMed ID: 27853651
[TBL] [Abstract][Full Text] [Related]
14. Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.
Entezari AA; Snook AE; Waldman SA
Expert Opin Ther Targets; 2021 May; 25(5):335-346. PubMed ID: 34056991
[TBL] [Abstract][Full Text] [Related]
15. Guanylyl cyclase C signaling axis and colon cancer prevention.
Pattison AM; Merlino DJ; Blomain ES; Waldman SA
World J Gastroenterol; 2016 Sep; 22(36):8070-7. PubMed ID: 27688649
[TBL] [Abstract][Full Text] [Related]
16. Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer.
Caspi A; Entezari AA; Crutcher M; Snook AE; Waldman SA
Per Med; 2022 Sep; 19(5):457-472. PubMed ID: 35920071
[TBL] [Abstract][Full Text] [Related]
17. Comparison of receptors for Escherichia coli heat-stable enterotoxin: novel receptor present in IEC-6 cells.
Mann EA; Cohen MB; Giannella RA
Am J Physiol; 1993 Jan; 264(1 Pt 1):G172-8. PubMed ID: 8381596
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of colorectal cancer: new perspectives after a long path.
Correale P; Botta C; Ciliberto D; Pastina P; Ingargiola R; Zappavigna S; Tassone P; Pirtoli L; Caraglia M; Tagliaferri P
Immunotherapy; 2016 Nov; 8(11):1281-1292. PubMed ID: 27993089
[TBL] [Abstract][Full Text] [Related]
19. Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells.
Waldman SA; Fortina P; Surrey S; Hyslop T; Kricka LJ; Graves DJ
Future Oncol; 2006 Dec; 2(6):705-16. PubMed ID: 17155897
[TBL] [Abstract][Full Text] [Related]
20. Cytokine adjuvanation of therapeutic anti-tumor immunity targeted to cancer mucosa antigens.
Snook AE; Huang L; Schulz S; Eisenlohr LC; Waldman SA
Clin Transl Sci; 2008 Dec; 1(3):263-4. PubMed ID: 19956776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]